Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline - Johnson & Johnson

J&J commits $3.5B for oncology—$1B Firefly Bio buy plus $2.58B Sail partnership option—targeting KRAS-driven solid tumors. The deal underscores biotech M&A competition as startups command higher valuations; 2026 EPS drag estimated at $0.46.